Glaxo Lotronex Indication Would Cover One-Third Of IBS Patients
Executive Summary
The recommended indication for Glaxo Wellcome's irritable bowel syndrome therapy Lotronex would cover about one-third of the U.S. IBS population.
You may also be interested in...
GSK Lotronex Indication Suggests Potential Market Of $280 Mil.
GlaxoSmithKline's narrowed Lotronex indication gives the product a potential market approximately the size of the company's U.S. hepatitis vaccine market in 2001
GSK Lotronex Indication Suggests Potential Market Of $280 Mil.
GlaxoSmithKline's narrowed Lotronex indication gives the product a potential market approximately the size of the company's U.S. hepatitis vaccine market in 2001
GSK Lotronex Plan Follows Accutane Model; Relaunch “Months” Away
GlaxoSmithKline's Lotronex risk management program will follow the Accutane model